INCY
IncyteNASDAQHealth CareBiotechnologySnapshot 2026-05-08
As of May 8, 2026, INCY has a composite score of 25.4 and is labeled with a signal of "mild favorable." This score is influenced by a medium confidence level of 71.9 and reflects various factors, including a macro score of 31.5 and a valuation score of 74.1, which is considered inexpensive. The analysis is provisional, indicating that the information may be subject to change.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share0.03
- Slope (norm)-0.65
- Bonus0.00
Why this rank
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $1.78 → $1.84 (+3.4% / 30d). 9 raised, 4 cut, 17 covering analysts.
0 upgrades, 0 downgrades / 30d, 4 maintained. 42% of analysts rate Buy.
1 PT revisions / 30d. Avg target -7.9% above current price.
1 positive, 0 negative / 30d. See F4 management tile for the event list.
Transition story with positive analyst positioning — often a turnaround setup.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
10 material events in the last 24 months — top 5 listed below.
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Increase Hematology and Oncology salesgrowthbehind7% progress
4/28: “CEO: 'Hematology and Oncology portfolio net sales of $204 million, an increase of 116%.'”
Why this status
Stated in 2 of last 2 quarters. Hematology and Oncology portfolio net sales increased from $94.44 million in 2025-Q1 to $204 million in 2026-Q1, a 116% increase. The trajectory shows strong growth in this segment, aligning with management's stated priority.
- 2.Manage R&D and SG&A expensescostbehind7% progress
2/10: “CEO: 'Total GAAP R&D and SG&A operating expenses of $3,495 to $3,675 million.'”
Why this status
Stated in 2 of last 2 quarters. Total GAAP R&D and SG&A operating expenses are guided to be between $3,495 to $3,675 million for 2026. The expenses have been consistently managed, with R&D at $611.4 million and SG&A at $390.4 million in 2025-Q4, indicating a focus on cost management.
- 3.Achieve product revenue targetsgrowthbehind7% progress
2/10: “CEO: 'Total net product revenue guidance of $4.77 to $4.94 billion.'”
Why this status
Stated in 2 of last 2 quarters. Total net product revenue for 2025 was $4.35 billion, with guidance for 2026 set at $4.77 to $4.94 billion. The company is focused on achieving these targets, with a 20% increase in total net sales in 2026-Q1 compared to 2025-Q1, indicating progress towards the goal.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 28%; 252d 32%.
Drawdown — Max 1y −18%. Bad day move −3%.
Beta to sector ETF (XLV) — 0.94 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 46/100, drawdown 63/100, beta 94/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Increase Hematology and Oncology sales
GrowthNew since 2026-05-04Focus on boosting sales in the Hematology and Oncology segment.
BehindStated in 2 of last 2 quarters. Hematology and Oncology portfolio net sales increased from $94.44 million in 2025-Q1 to $204 million in 2026-Q1, a 116% increase. The trajectory shows strong growth in this segment, aligning with management's stated priority.
7%CEO/CFO:“CEO: 'Hematology and Oncology portfolio net sales of $204 million, an increase of 116%.'”Press releaseSource dated 2026-04-28Stated 2 of last 8 quartersFirst seen 2026-05-04Show history (2)
- 2026-Q1Press release
“CEO: 'Hematology and Oncology portfolio net sales of $204 million, an increase of 116%.”
- 2025-Q4Press release
“CEO: 'Total net product revenue for Hematology and Oncology increased.'”
- #2
Manage R&D and SG&A expenses
CostNew since 2026-05-04Maintain control over R&D and SG&A expenses to optimize financial performance.
BehindStated in 2 of last 2 quarters. Total GAAP R&D and SG&A operating expenses are guided to be between $3,495 to $3,675 million for 2026. The expenses have been consistently managed, with R&D at $611.4 million and SG&A at $390.4 million in 2025-Q4, indicating a focus on cost management.
7%CEO/CFO:“CEO: 'Total GAAP R&D and SG&A operating expenses of $3,495 to $3,675 million.'”Press releaseSource dated 2026-02-10Stated 2 of last 8 quartersFirst seen 2026-05-04Show history (2)
- 2026-Q1Press release
“CEO: 'Total GAAP R&D and SG&A operating expenses of $3,495 to $3,675 million.'”
- 2025-Q4Press release
“CEO: 'R&D expenses were $611.4 million, SG&A expenses were $390.4 million.'”
- #3
Achieve product revenue targets
GrowthNew since 2026-05-04Strive to meet or exceed product revenue targets across key segments.
BehindStated in 2 of last 2 quarters. Total net product revenue for 2025 was $4.35 billion, with guidance for 2026 set at $4.77 to $4.94 billion. The company is focused on achieving these targets, with a 20% increase in total net sales in 2026-Q1 compared to 2025-Q1, indicating progress towards the goal.
7%CEO/CFO:“CEO: 'Total net product revenue guidance of $4.77 to $4.94 billion.'”Press releaseSource dated 2026-02-10Stated 2 of last 8 quartersFirst seen 2026-05-04Show history (2)
- 2026-Q1Press release
“CEO: 'Total net product revenue guidance of $4.77 to $4.94 billion.'”
- 2025-Q4Press release
“CEO: 'Total net product revenue for the full year of 2025 was $4.35 billion.'”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
P/E over the last 5 years
40 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
INCY Incyte | +25 | inexpensive | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is raised (currently NEW as of 2026-04-28)+4.0 pts
- If next-quarter guidance is cut (currently NEW as of 2026-04-28)-8.0 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-04-2810d agoItem 2.02
Results of Operations and Financial Condition. On April 28, 2026 , Incyte Corporation issued a press release announcing financial results for its first fiscal quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1.
earnings preannouncementpositivescore 57 - 2026-03-301mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 26, 2026, Susanne Schaffert notified Incyte Corporation (the “Company”) that she was resigning from the Company’s Board of Directors (the “Board”), effective as of April 15, 2026. The resignation of Dr. Schaffert, who has been a member of the Company’s Board since 2022, was not the result of any disagreement with the Company on any matter…
executive changeneutralscore 23 - 2026-03-261mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 25, 2026, Incyte Corporation (the “Company”) announced title changes for certain current members of its executive leadership team, effective immediately. Pablo J. Cagnoni’s title was changed to President, Incyte and Global Head of Research and Development; Steven H. Stein’s title was changed to Executive Vice President, Chief Medical Offic…
executive changeneutralscore 21 - 2026-03-062mo agoItem 8.01
Other Events. On February 27, 2026, the U.S. Food and Drug Administration (“FDA”) issued a Complete Response Letter (“CRL”) for the supplemental Biologics License Application (“sBLA”) for Zynyz® (retifanlimab-dlwr) injection (375mg) for an additional indication for the treatment of adult patients with metastatic non-small cell lung cancer (“NSCLC”) in combination with platinum-based chemotherapy. The sBLA was supported by positive efficacy and safety data from the Phase 3 POD1UM-304 trial ann…
legal regulatorynegativescore 12 - 2026-02-102mo agoItem 2.02
Results of Operations and Financial Condition. On February 10, 2026, Incyte Corporation issued a press release announcing financial results for its fourth fiscal quarter and year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1.
earnings preannouncementneutralscore 9
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.